Novo Nordisk hypertension candidate ocedurenone fails in phase 3
2024-06-26
JHVEPhoto/iStock Editorial via Getty Images Novo Nordisk (NVO) said that ocedurenone, under investigation for uncontrolled hypertension in chronic kidney disease patients, missed its primary endpoint in a phase 3 trial. That endpoint was change in systolic blood pressure from baseline to week 12. As a result, the Danish pharma isContinue Reading